Recently Featured

Celiac Disease Study Reveals Fiber Benefits Depend on Gut Microbiome

April 2, 2026
The recent study published in Nature Communications highlights a critical finding regarding celiac disease: the benefits of dietary fiber are significantly influenced by the gut microbiome. Celiac disease, an autoimmune disorder triggered by gluten, leads to mucosal damage in the small intestine and often results in nutrient deficiencies, including fiber. While patients are typically advised…

FDA flags serious liver injury cases, 8 deaths with ‘reasonable’ link to Amgen’s Tavneos

April 2, 2026
The U.S. Food and Drug Administration (FDA) has identified 76 cases of drug-induced liver injury associated with Amgen’s Tavneos, a treatment primarily indicated for the management of certain autoimmune conditions. Among these cases, eight fatalities were reported, raising significant concerns regarding the safety profile of the drug. This alarming data comes as the FDA continues…

Novo Nordisk cuts 400 roles at troubled Bloomington site

April 2, 2026
Amid a significant corporate restructuring, Novo Nordisk has announced the elimination of 400 positions at its Bloomington, Indiana production facility. This site plays a crucial role in the manufacturing of the company’s high-demand GLP-1 medications, including the blockbuster drugs Ozempic and Wegovy. The decision to downsize comes as part of a broader strategy to streamline…

Viridian tumbles on positive data for key eye drug prospect

April 2, 2026
Viridian’s recent announcement regarding positive data for its key eye drug prospect has led to a notable decline in its stock price. Despite the favorable results, investor expectations were not met, prompting concerns about the commercial viability of the treatment. An analyst has indicated that this discrepancy could ignite fierce debates among investors regarding the…

Ongoing Cases